VAKCINA

Thomas Sankara wrote:jeste, kinesku najklasicniju mogucu vakcinu je teze napraviti nego vakcinu mRna tehnologije, prvu u istoriji. hajde da se drogiramo da nam oci sjaje. bajdenu pederu pokrao si srbiju

Turul madár wrote:nisam nigde rekao da je proizvodnja kineske vakcine najjeftinija, dakle to si izmislio, nego da je to tehnologija po kojoj bismo mi i slične zemlje mogli najlakše da preuzmemo proizvodnju, odnosno proizvode se po već poznatoj tehnologiji, za razliku od zapadnih za koje postoji sasvim novi proces.

al ajde nastavi zanimljivo je

Argentina's president said Sinopharm's asking price for its Beijing inactivated Covid vaccine was triple the price they're getting Sputnik V for - but negotiating down to double the price (US$20 per dose), pending Anmat (drug regulator) authorization https://t.co/QsahPVRx8R

— Hilda Bastian, PhD (@hildabast) February 8, 2021

Bharat Biotech announces reduction in COVID-19 vaccine price for states to Rs 400/dose from Rs 600

— Press Trust of India (@PTI_News) April 29, 2021

While adding additional antigens to mRNA and vector-based vaccines would slow down production times for these rapidly produced vaccines, another popular vaccine approach already has the advantage of triggering the immune system to recognize multiple parts of the virus: inactivated SARS-CoV-2 viruses. This approach involves producing large amounts of virus in cell culture, then treating the viruses with a chemical to render them no longer infectious. This process can take more time—not to mention the challenges of standardizing inactivation and conducting essential quality checks to ensure the virus is indeed safe—and so vaccines of this type have lagged behind mRNA and vector-based vaccines. But the upside is that the immune system sees an entire virus, not just the spike protein.

RNA based vaccines, which are relatively quick and inexpensive to make and may be safer to use could herald more rapid control over the spread of infectious diseases, including COVID-19.
...
RNA based vaccines could have an impact in these areas due to their shorter manufacturing times and greater effectiveness.
...
RNA vaccines are faster and cheaper to produce than traditional vaccines, and a RNA based vaccine is also safer for the patient, as they are not produced using infectious elements
...
Production of RNA vaccines is laboratory based, and the process could be standardised and scaled, allowing quick responses to large outbreaks and epidemics
...
A major advantage of RNA vaccines is that RNA can be produced in the laboratory from a DNA template using readily available materials, less expensively and faster than conventional vaccine production, which can require the use of chicken eggs or other mammalian cells.

Talason wrote:

Turul madár wrote:nisam nigde rekao da je proizvodnja kineske vakcine najjeftinija, dakle to si izmislio, nego da je to tehnologija po kojoj bismo mi i slične zemlje mogli najlakše da preuzmemo proizvodnju, odnosno proizvode se po već poznatoj tehnologiji, za razliku od zapadnih za koje postoji sasvim novi proces.

al ajde nastavi zanimljivo je

ako je postupak kraći i jeftiniji, znači da ti je samo potrebna investicija

Turul madár wrote:

Talason wrote:

ako je postupak kraći i jeftiniji, znači da ti je samo potrebna investicija

a kadrovi, patenti? kako bi ovladali  tehnologijom kojom su napravili fajzer, modernu, az bez ta dva?

načinom kako su kinezi došli do vakcine su se pravile vakcine i kod nas u institutima. a naši su za ovaj virus jedino uspeli da ga izoluju valjda, to je neka početna tačka da bi se moglo dalje raditi.

San Saba Songbird wrote:skaliranje proizvodnje inaktiviranih vakcina je velika jebenica i zato to puno košta. Talason je u pravu, kao i uvek kad je reč o proizvodnji.

Vilmos Tehenészfiú wrote:

San Saba Songbird wrote:skaliranje proizvodnje inaktiviranih vakcina je velika jebenica i zato to puno košta. Talason je u pravu, kao i uvek kad je reč o proizvodnji.

pacejah te gleda.